Small Molecules

17 Jun 2020 ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
17 Jun 2020 Recordati: Isturisa® (osilodrostat) phase III LINC-4 trial meets its primary endpoint in Cushing’s disease
17 Jun 2020 Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
17 Jun 2020 Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
16 Jun 2020 C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
16 Jun 2020 Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
16 Jun 2020 Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study
16 Jun 2020 Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
15 Jun 2020 Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)
15 Jun 2020 Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)
15 Jun 2020 Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association's Scientific Sessions
15 Jun 2020 Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction
15 Jun 2020 Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
15 Jun 2020 Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma
15 Jun 2020 Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
13 Jun 2020 Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
13 Jun 2020 Forma Therapeutics Presents Safety, Pharmacokinetic and Pharmacodynamic Data from Phase 1 Clinical Trial for Investigational Agent FT-4202 in Patients with Sickle Cell Disease
13 Jun 2020 Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults With Spinal Muscular Atrophy (SMA)
13 Jun 2020 Positive Phase III Results for Venclexta Combination in Acute Myeloid Leukemia Presented At EHA 2020
13 Jun 2020 Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy
11 Jun 2020 Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
11 Jun 2020 Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
10 Jun 2020 Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
10 Jun 2020 Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
10 Jun 2020 Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up